Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers - Wikidata - awgldk - TriplyDB

Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers

Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers

http://www.wikidata.org/entity/Q27702093

about

KRAS Mutant Pancreatic Cancer: No Lone Path to an Effective Treatment Negative feedback regulation of the ERK1/2 MAPK pathway Molecular dynamics simulations and modelling of the residue interaction networks in the BRAF kinase complexes with small molecule inhibitors: probing the allosteric effects of ligand-induced kinase dimerization and paradoxical activation.Exploring Molecular Mechanisms of Paradoxical Activation in the BRAF Kinase Dimers: Atomistic Simulations of Conformational Dynamics and Modeling of Allosteric Communication Networks and Signaling Pathways.Comprehensive pharmacological profiling of neurofibromatosis cell lines.Treatment of NRAS-mutated advanced or metastatic melanoma: rationale, current trials and evidence to date Targeting mutant NRAS signaling pathways in melanoma.BRAF(V600E) Kinase Domain Duplication Identified in Therapy-Refractory Melanoma Patient-Derived Xenografts Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.LY3009120, a panRAF inhibitor, has significant anti-tumor activity in BRAF and KRAS mutant preclinical models of colorectal cancer Obatoclax and LY3009120 Efficiently Overcome Vemurafenib Resistance in Differentiated Thyroid Cancer CRAF gene fusions in pediatric low-grade gliomas define a distinct drug response based on dimerization profiles.Rational design, synthesis, and biological evaluation of Pan-Raf inhibitors to overcome resistance.The renewed battle against RAS-mutant cancers.An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling.Phosphoproteomics Reveals MAPK Inhibitors Enhance MET- and EGFR-Driven AKT Signaling in KRAS-Mutant Lung Cancer.Drugging RAS: Know the enemy.Strategies for monitoring and combating resistance to combination kinase inhibitors for cancer therapy.Challenges in the delivery of therapies to melanoma brain metastases.Overcoming resistance to BRAF inhibitors.Molecular modeling and structure-based drug discovery approach reveals protein kinases as off-targets for novel anticancer drug RH1.RAF inhibitors promote RAS-RAF interaction by allosterically disrupting RAF autoinhibition.Targeting the Raf kinases in human cancer: the Raf dimer dilemma.KRAS: The Critical Driver and Therapeutic Target for Pancreatic Cancer.New perspectives for targeting RAF kinase in human cancer.BRAF inhibition upregulates a variety of receptor tyrosine kinases and their downstream effector Gab2 in colorectal cancer cell lines.Targeting melanoma stem cells with the Vitamin E derivative δ-tocotrienol.A brain-penetrant RAF dimer antagonist for the noncanonical BRAF oncoprotein of pediatric low-grade astrocytomas.Acetylsalicylic Acid Governs the Effect of Sorafenib in RAS- Mutant Cancers.Pan-Raf co-operates with PI3K-dependent signalling and critically contributes to myeloma cell survival independently of mutated RAS.Wnt/β-catenin pathway activation mediates adaptive resistance to BRAF inhibition in colorectal cancer.Receptor tyrosine kinases and downstream pathways as druggable targets for cancer treatment: the current arsenal of inhibitors.RAF inhibitor LY3009120 sensitizes RAS or BRAF mutant cancer to CDK4/6 inhibition by abemaciclib via superior inhibition of phospho-RB and suppression of cyclin D1.Type II RAF inhibitor causes superior ERK pathway suppression compared to type I RAF inhibitor in cells expressing different BRAF mutant types recurrently found in lung cancer.Targeting KRAS in metastatic colorectal cancer: current strategies and emerging opportunities.Gastrin inhibits gastric cancer progression through activating the ERK-P65-miR23a/27a/24 axis.

P2860

Q26751520-0886C10C-00E1-4BDD-B27F-575DF2AE67BA Q28079202-37305249-1F9E-42C9-BC83-2389EFE0C3E0 Q30391310-1684F85C-9460-437C-83A0-413E108C07BA Q30395364-959C9F64-2C2D-4886-A20F-B8835B352011 Q33622690-E0301A0B-5AA6-4F7D-B897-95DD8A2D86E1 Q33887664-3781EA39-C02E-4A0B-A456-2832C6F92A3A Q36902066-33759514-AB92-472E-81DC-13363A99D3E3 Q37056708-243ACFAA-CF69-46C0-BE25-7CE1B87F6E0E Q37632230-515944E5-375A-4098-96AC-3B07864B63DE Q37705948-9EAEF06D-54C5-4759-8C44-42EEC73D5D71 Q37738239-7F098771-B189-41D5-A7DE-1D78BD8E2163 Q38625816-BF7DFC5A-27C3-4E4E-918B-CA52B79E1708 Q38709303-A5CC663C-A52A-4C27-8A0B-50C3F0D70036 Q38740000-1D8FC915-9164-41A1-ACD3-3867C8DA4D6B Q38752000-640B89E2-2F3F-4415-9587-3D5BD765720E Q38757884-C31F1C9A-81E9-4550-A3C0-B2A69A5C10A5 Q39182842-394BD6AA-7E4A-4D11-BC34-789500F22F28 Q39255218-DB7CF506-C12D-43F0-8CFC-6DA64B579015 Q39331752-2D490BCC-C065-484B-90F9-EF367B5D8C08 Q43298157-BFDF7457-6E70-486F-850A-F0E4232B637B Q46311028-B2B21AE7-FE4C-4ECF-9CA8-AC343252F252 Q47144509-0F6F2FC0-9EDA-4421-8D3D-9F2CA45C7169 Q47279988-82AEC4B5-0752-4AB5-9B68-7C51A3310EFE Q47563012-51A9A0F4-F491-42FF-BFF0-5A5050D438B4 Q47688064-57F91CC1-FEA4-4995-B12D-EB7642C0063D Q47736865-6A8531C6-0850-4560-9FB3-585E990C3741 Q48251370-40E0B2F3-13B1-4C9C-9F38-A82D1577F882 Q48360152-6E3C1811-D377-42E6-A744-2C38F441826E Q48583910-61B86A24-726C-418E-9E9E-11D508AC7E00 Q49021003-64F85727-803C-4D87-A6DB-BCEC15329104 Q49788106-E17B8931-C8EA-43E3-958D-DE560CCC585E Q49887919-5ADD7B7C-4F88-44AD-AB63-01E5F6B9951C Q50068807-ACA21F1B-9006-4345-9494-13E0CE612398 Q54115748-8D15218D-3176-44E1-BF14-2E3C9D40A312 Q54962055-83390083-EA3E-42A8-B466-3A9ED0B27857 Q54977122-74251AD1-F938-4113-8107-954484CDB7F8

P2860

Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers

http://www.wikidata.org/entity/Q27702093

description

2015 nî lūn-bûn

@nan

2015 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Inhibition of RAF Isoforms and ...... in RAS or BRAF Mutant Cancers

@ast

Inhibition of RAF Isoforms and ...... in RAS or BRAF Mutant Cancers

@en

Inhibition of RAF Isoforms and ...... in RAS or BRAF Mutant Cancers

@nl

type

label

Inhibition of RAF Isoforms and ...... in RAS or BRAF Mutant Cancers

@ast

Inhibition of RAF Isoforms and ...... in RAS or BRAF Mutant Cancers

@en

Inhibition of RAF Isoforms and ...... in RAS or BRAF Mutant Cancers

@nl

prefLabel

Inhibition of RAF Isoforms and ...... in RAS or BRAF Mutant Cancers

@ast

Inhibition of RAF Isoforms and ...... in RAS or BRAF Mutant Cancers

@en

Inhibition of RAF Isoforms and ...... in RAS or BRAF Mutant Cancers

@nl

P1433

Q27702093-0CA85212-0C27-47E1-9B56-F4460B0DDB48

P1476

Q27702093-27FF388C-AB4E-4EE1-812F-AD53B414003E

P2093

Q27702093-00631405-41A6-4BA9-8E6D-B30FC7017568

Q27702093-00F85B2A-7C6A-4A6A-99E0-9761233B23F7

Q27702093-050A9A30-6146-4D17-9F83-3046896028DD

Q27702093-076DA4FF-615B-4C69-A0D4-39BDD45220A4

Q27702093-0A3C97A9-3B4E-4603-971D-E84E14503A6C

Q27702093-18F9B864-F15C-4982-BCBD-5DD95E4E5C32

Q27702093-2EBBE6FC-B6F9-478F-AAE1-1D0E48755497

Q27702093-31466B5F-AB6C-4436-8BB9-DF3BB411A5FE

Q27702093-3387F4FC-C608-48B5-B8C8-0FEC05FBC068

Q27702093-3F1EEC30-D5A8-4813-B6C0-791ED16B612A

P304

Q27702093-BF093EC1-7946-41F4-BF22-8BD16A9D3F12

P31

Q27702093-50A2635D-3D6E-4FDE-B2A8-FF28D27A94F1

P3181

Q27702093-75170FA9-1354-4564-88BB-C1118F492973

P356

Q27702093-4B4005C1-8D58-4588-98F9-EAEBAC726AB2

P433

Q27702093-43D02460-82B7-483F-A2A5-9BD94D157B22

P478

Q27702093-51439779-7247-4CF3-BB54-EA43D64F5344

P577

Q27702093-9F956659-CD08-461C-AFC8-7A8E388C9F8C

P5875

Q27702093-EBC56F1C-2857-4FE0-94DE-C6F43C1960F1

P698

Q27702093-0A80F405-1D8E-4424-B4E8-C549DB720BE9

P3181

P356

J.CCELL.2015.08.002

P1433

P1476

Inhibition of RAF Isoforms and ...... in RAS or BRAF Mutant Cancers

@en

P2093

Bryan D Smith

http://www.w3.org/2001/XMLSchema#string

Daniel L Flynn

http://www.w3.org/2001/XMLSchema#string

Denis McCann

http://www.w3.org/2001/XMLSchema#string

Gregory D Plowman

http://www.w3.org/2001/XMLSchema#string

Gregory P Donoho

http://www.w3.org/2001/XMLSchema#string

Igor Mochalkin

http://www.w3.org/2001/XMLSchema#string

Ilaria Conti

http://www.w3.org/2001/XMLSchema#string

James J Starling

http://www.w3.org/2001/XMLSchema#string

James R Henry

http://www.w3.org/2001/XMLSchema#string

Jennie Walgren

http://www.w3.org/2001/XMLSchema#string

P304

384-98

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

744507

http://www.w3.org/2001/XMLSchema#string

P356

10.1016/J.CCELL.2015.08.002

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

28

http://www.w3.org/2001/XMLSchema#string

P577

2015-09-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

281607157

http://www.w3.org/2001/XMLSchema#string

P698

26343583

http://www.w3.org/2001/XMLSchema#string